LPC20K modified from krill oil ameliorates the scopolamine-induced cognitive impairment.
Krill oil
Long-term memory
MAPK/CaMKⅡ-BDNF signaling pathway
Recognition memory
lysophosphatidylcholine-docosahexaenoic acid
Journal
Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872
Informations de publication
Date de publication:
23 Dec 2023
23 Dec 2023
Historique:
received:
15
08
2023
revised:
22
12
2023
accepted:
22
12
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
25
12
2023
Statut:
aheadofprint
Résumé
Alzheimer's disease (AD) is characterized by cognitive impairment. It is common in the elderly. Etiologically, dysfunction of cholinergic neurotransmitter system is prominent in AD. However, disease modifying drug for AD is still unavailable. We hypothesized that krill oil and modified krill oil containing 20% lysophosphatidylcholine-docosahexaenoic acid (LPC-DHA, LPC20K) could play a crucial role in AD by improving cognitive functions measured by several behavioral tests. We found that LPC20K could ameliorate short-term, long-term, spatial, and object recognition memory under cholinergic hypofunction states. To find the underlying mechanism involved in the effect of LPC20K on cognitive function, we investigated changes of signaling molecules using Western blotting. Expression levels of protein kinase C zeta (PKCζ) and postsynaptic density protein 95 (PSD-95), and phosphorylation levels of extracellular signal-regulated kinase (ERK), Ca
Identifiants
pubmed: 38145873
pii: S0166-4328(23)00554-5
doi: 10.1016/j.bbr.2023.114836
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114836Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Author declarations The authors declare that there are no conflicts of interest.